Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis

Lupus

Volumn 21, Issue 13, 2012, Pages 1444-1449

  Nomura, A ^a,b   Shimizu, H ^a   Kishimoto, M ^a   Suyama, Y ^a   Rokutanda, R ^a   Ohara, Y ^a   Yamaguchi, K ^a   Okada, M ^a  

^a ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^b CHUBU ROSAI HOSPITAL   (Japan)

Author keywords

Combination therapy; lupus nephritis; mizoribine; systemic lupus erythematosus; tacrolimus

Indexed keywords

GLUCOCORTICOID; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; TACROLIMUS;

ACTIVE NEPHRITIS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; FEMALE; HUMAN; MALE; NEPHRITIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION;

ADULT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RIBONUCLEOSIDES; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867833980     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203312458468     Document Type: Article

References (14)

1. Karim Y, D'Cruz DP. The NIH pulse cyclophosphamide regime: the end of an era?. Lupus. 2004 ; 13: 1-3
2. Ginzler EM, Dooly MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 ; 353: 2219-2228
3. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009 ; 20: 1103-1112
4. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011 ; 57: 235-244
5. Bao H, Liu ZH, Wie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol. 2008 ; 19: 2001-2010
6. Yumura W, Suganuma S, Uchida K, et al. Effect of long-term treatment with mizoribine in patients with proliferative lupus nephritis. Clin Nephrol. 2005 ; 64: 28-34
7. Tanabe K, Tokumoto T, Ishikawa N, et al. Long-term results in mizoribine-treated renal transplant recipients: a prospective, randomized trial of mizoribine and azathioprine under cyclosporine-based immunosuppression. Transplant Proc. 1999 ; 31: 2877-2879
8. Dall'Era M. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2011 ; 23: 454-458
9. Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis. Ann Rheum Dis. 2010 ; 69: 2083-2089
10. Li X, Ren H, Zhang Q, et al. Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis. Nephrol Dial Transplant. 2012 ; 27: 1467-1472
11. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med. 2007 ; 357: 2562-2575
12. Lanata CM, Mahmood T, Fine DM, et al. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus. 2010 ; 19: 935-940
13. Yokota S. Mizoribine: mode of action and effects in clinical use. Pediatr Int. 2002 ; 44: 196-198
14. Tanaka H, Oki E, Tsuruga K, et al. Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis. Clin Rheumatol. 2010 ; 29: 1049-1054